https://durbinglobal.com/news/cross-border-expanded-access-programs-reducing-barriers-to-treatment-access/2023-01-30T11:23:40+00:00https://durbinglobal.com/news/sifi-and-durbin-announce-the-opening-of-an-early-access-program-for-akantior-the-treatment-of-acanthamoeba-keratitis/2023-01-30T11:21:50+00:00https://durbinglobal.com/news/evaluating-the-cost-impact-of-an-expanded-access-program/2023-01-30T11:15:55+00:00https://durbinglobal.com/news/3-key-steps-to-bring-eaps-to-a-global-market/2023-01-30T11:15:00+00:00https://durbinglobal.com/news/the-real-value-of-mapping-the-expanded-access-program-eap-ecosystem/2023-01-30T11:14:04+00:00https://durbinglobal.com/news/benefits-challenges-and-practicalities-of-collecting-real-world-data-during-expanded-access-programs/2023-01-30T11:13:17+00:00https://durbinglobal.com/news/the-expanded-access-program-eap-playbook/2023-01-30T11:10:59+00:00https://durbinglobal.com/news/zogenix-launches-global-access-program-for-fintepla-fenfluramine-oral-solution/2023-01-30T11:10:20+00:00https://durbinglobal.com/news/optimizing-commercial-launch-for-orphan-drugs-with-expanded-access-programs/2023-01-30T11:09:27+00:00